Oncology
Page 4 • 12 itemsGlobal oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Perceptive Discovery Partners with MH3D to Launch α-Sight™ Alpha Radiopharmaceutical Imaging Platform
Perceptive Discovery announces strategic partnership with MH3D and launches α-Sight™ preclinical imaging platform for alpha-emitting radiopharmaceuticals in oncology.
Florida Cancer Specialists & Research Institute Advances Medically Integrated Oncology Care Model
Florida Cancer Specialists & Research Institute showcases leadership in medically integrated oncology care, improving patient outcomes through innovative treatment models.
Phrontline Biopharma's TJ106 Shows Promise Against HER2-Low and Drug-Resistant Cancers in Preclinical Studies
Phrontline Biopharma presents preclinical data for TJ106, a biparatopic HER2 ADC showing activity in HER2-low and resistant tumors at AACR 2026.
Telix Pharmaceuticals Doses First Patient in Phase 3 Trial of TLX101-Tx for Recurrent Glioblastoma
Telix begins Phase 3 IPAX-BrIGHT trial of TLX101-Tx, marking the first radiopharmaceutical therapy to reach Phase 3 for recurrent glioblastoma treatment.
NMPA Expedited Approval Oncology: Impact on Cancer Drug Access in China
The NMPA's expedited approval process is transforming cancer drug access in China, significantly impacting treatments like osimertinib for lung cancer patients.
NMPA Priority Review Granted to AI Diagnostic Tool for Early Cancer Detection
The NMPA has granted priority review to an innovative AI diagnostic tool designed for early cancer detection, promising to revolutionize patient outcomes.
![NMPA Priority Review Granted to [Drug Name] for Lung Cancer](/uploads/articles/nmpa-priority-review-drugname-lung-cancer-2024.webp)
NMPA Priority Review Granted to [Drug Name] for Lung Cancer
[Drug Name] has received NMPA priority review for lung cancer, potentially revolutionizing patient care and treatment outcomes in this critical area.
NMPA Grants Breakthrough Therapy Designation to Innovent's KRAS G12C Inhibitor
The NMPA has granted breakthrough therapy designation to Innovent's KRAS G12C inhibitor, marking a significant advancement in the treatment of advanced solid tumors.
PMDA Expedited Review Melanoma: Impact on Japanese Treatment Paradigms
The PMDA's expedited review process for melanoma therapies, including Keytruda, is transforming treatment paradigms in Japan, enhancing patient access to innovative care.
Australian Biotech Solid Tumor CAR-T: What You Need to Know
Explore the advancements in Australian Biotech's CAR-T therapy for solid tumors, offering new hope for patients battling cancer.
PMDA Biosimilar Framework: Impact on Trastuzumab Biosimilars in Japan
This article delves into the PMDA biosimilar framework and its significant influence on the development and approval of trastuzumab biosimilars in Japan.
Bevacizumab Biosimilar Approval China: NMPA Greenlights First Biosimilar
The NMPA has approved the first biosimilar of Bevacizumab, a groundbreaking step for cancer treatment accessibility in China.